Squamous Cell Carcinoma Treated With Intralesional Methotrexate: Report of a Case

Sancheza DCV, Gonzalezb LGV, Hernandezc LM and Moreno GC

Published on: 2022-05-07


Squamous cell carcinoma (SSC) is the second most common cutaneous malignancy. Some reports have mentioned the use of intralesional methotrexate as a neoadjuvant therapy to reduce the tumor´s size and enable a smaller surgical defect and reconstruction area. Among the multiple advantages of this approach, some stand out, like bypassing the systemic side effects of chemotherapy that present when administered PO or IV. Methotrexate is one of the most used drugs for skin SCC. Its intralesional administration allows a satisfactory pharmaceutical concentration level (>104 ) in the tumoral cells, turning them more sensitive to the cytotoxic effect causing tissue necrosis, thus reducing the tumors mass and enabeling a better surgical outcome.